Polarean Imaging Plc (PLLWF)
OTC PINK OTC PINK Primary 
Polarean Imaging expands commercial arrangement with Ascend to 19 states
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has expanded its commercial agreement with Ascend Imaging, increasing coverage for its Xenon MRI platform from four to 19 US states. The company said the expanded arrangement will enhance sales efforts and strengthen access to healthcare institutions adopting functional lung imaging.
Polarean boost as analyst repeats 'buy' rating and 4p price target
Stifel on Monday reiterated its 'buy' rating on shares in Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) with a 4p price target, a significant premium to the current 0.46p valuation. The spur is progress at the University of Virginia Health, where Polarean has just signed a supply deal that will see the hospital fully equipped with clinical-grade “hyperpolarisers”.
Polarean Imaging lands latest contract in US, with University of Virginia Health
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has landed a new supply agreement with the University of Virginia Health, which is upgrading to complete the transition to full clinical Xenon MRI capabilities. The deal provides additional equipment for clinical use, following UVA's upgrade of two hyperpolariser systems last year.
Polarean Imaging plc (PLLWF) Q2 2025 Earnings Call Transcript
Polarean Imaging plc (OTCPK:PLLWF) Q2 2025 Earnings Call September 25, 2025 10:00 AM EDT Company Participants Christopher Von Jako - CEO & Director Charles Osborne - CFO & Director Presentation Operator Good afternoon, and welcome to the Polarean Imaging plc Investor Presentation. [Operator Instructions] Before we begin, I'd like to submit the following poll.
Polarean amends sales guidance as Trump bill creates headwinds; sales pipeline remains strong
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) lowered its revenue outlook for 2025 after cuts to US medical research and hospital funding delayed purchasing decisions for its lung imaging systems. However, it provided a more upbeat, longer-term commercial assessment of demand for its xenon-based MRI technology.
Polarean Imaging up 15% on FDA submission news; broker repeats 'buy'
Polarean Imaging PLC's (AIM:POLX, OTC:PLLWF) shares surged 15% after the company submitted a phase III clinical trial protocol to the US Food and Drug Administration, aiming to broaden the use of its lung imaging agent, XENOVIEW. Already approved for ventilation imaging, Polarean hopes to expand XENOVIEW's indication to include quantitative gas-exchange imaging, a technique that measures how efficiently the lungs transfer gas from the air into the bloodstream, a vital sign of lung health.
Polarean shares rise 6% on new US sales deal; broker applauds tie-up
Shares in Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) rose 6% after the company announced a new commercial partnership with Ascend Imaging to boost US sales of its xenon-based MRI technology. The agreement, covering four states, allows Ascend to act as an independent sales representative, helping expand Polarean's footprint without growing its internal team.
Polarean shares rise 7% on expanded FDA approval for lung imaging agent
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) shares rose 7% in afternoon trading after the company received US regulatory approval to expand the use of its lung imaging agent, XENOVIEW, to children as young as six. The decision by the Food and Drug Administration lowers the age threshold from 12, potentially opening access to around one million additional patients.
Polarean wins US approval to use lung imaging tech in younger children
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has received approval from US regulators to expand the use of its lung imaging agent, XENOVIEW, to include children as young as six, opening access to an estimated one million additional patients. The decision by the Food and Drug Administration lowers the minimum approved age from 12 to six years, allowing clinicians to use XENOVIEW with magnetic resonance imaging (MRI) to assess how well air moves through the lungs in younger patients.
Polarean reaffirms 2025 guidance as it points to strong order pipeline
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) reaffirmed its full-year revenue guidance on Thursday, saying it expects to deliver between $5 million and $6 million in 2025, despite sector-wide funding pressures in its core US market. The company pointed to a strong order backlog, growing clinical demand and an expanded commercial team as reasons for confidence in second-half sales momentum.
Polarean Imaging: Bank walks away from capital markets day impressed; repeats 'buy'
Polarean Imaging PLC's (AIM:POLX, OTC:PLLWF) capital markets day has reaffirmed Stifel's confidence in its 'buy' recommendation, with the investment bank highlighting the company's improved commercial strategy and strong clinical potential. Stifel noted that the event reinforced the advantages of the company's Xenon MRI technology, which offers a detailed, non-invasive way to assess lung function.
Polarean Imaging shares up 5% after pharma deal; bank repeats 'buy'
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) shares climbed 5% in early trading after securing a major deal to expand its Xenon MRI technology into pharmaceutical research. A top global pharmaceutical company has selected Polarean's imaging services for a multi-centre clinical trial, which will evaluate an investigational lung treatment.
